Bausch Health, Glenmark announce approval of RYALTRIS in Canada ...Middle East

Business Standard - Economy
/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), are pleased to announce that RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.1 "This Health Canada approval will allow Bausch Health to soon make RYALTRI S available to Canadians, providing an innovative therapy option for seasonal allergic rhinitis," Cees Heiman, Senior Vice-President, Europe and Can

Hence then, the article about bausch health glenmark announce approval of ryaltris in canada was published today ( ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bausch Health, Glenmark announce approval of RYALTRIS in Canada )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in Economy


Latest News